Finasteride has no effect on prostate cancer survival

At the ASCO (American Society of Clinical Oncology) Genitourinary Cancers Symposium in February 2013, Goodman and colleagues presented a paper that summarized the long-term follow-up outcomes from the Prostate Cancer Prevention Trial. The original study was conducted from 1993 to 1997 and randomly assigned men to receive either 5 mg of finasteride or placebo, with the hope of reducing the odds of developing prostate cancer. Longterm follow-up, now at 15 years, showed no significant prostate cancer survival difference between patients treated with active drug or placebo. A subset analysis of men with low risk prostate cancer that had received finasteride did, however, have a better survival, although the cause of this effect was unclear.

2 Responses to Finasteride has no effect on prostate cancer survival

  1. Every word in this piece of work is very clear and your passion for this topic shines. Please continue your work in this area and I hope to see more from you in the future.